欢迎来到《四川大学学报(医学版)》

PET/CT真正全身显像在结外NK/T细胞淋巴瘤(鼻型)患者中的应用价值

The Application Value of True Whole-body PET/CT Scanning Protocol in Patients of Extranodal NK/T Cell Lymphoma

  • 摘要:
      目的  评价PET/CT真正的全身(true whole-body,TWB)显像较局限性全身(limited whole-body,LWB,头顶到大腿中份)显像增加的下肢远端这一显像范围对结外NK/T细胞淋巴瘤(鼻型)(extranodal natural killer/T-cell lymphoma,nasal type,ENKTL)患者的分期及随访评估的价值。
      方法  收集2012年1月至2017年9月在我科行TWB PET/CT显像的ENKTL患者。根据患者检查目的不同分为两组,一组为分期组,即初诊时行TWB PET/CT评估分期的患者;另一组为随访组,即用TWB PET/CT行随访评估的患者。随访患者根据有无行TWB PET/CT初诊分期以及随访检查前有无临床确诊或怀疑的LWB范围内肿瘤进展(progressive disease, PD),再分为有TWB PET/CT分期无PD、有TWB PET/CT分期有PD、无TWB PET/CT分期无PD、无TWB PET/CT分期有PD4个亚组。比较分期组和随访组各亚组发现下肢远端(LWB范围外)非预期ENKTL病灶的百分率(P1),和各组因此改变分期、再分期/疗效评价结果的百分率(P2)。
      结果  分期组患者225例,其中有200例(88.9%)肿瘤局限于LWB范围内,P1为11.1%(25例),P2为0.4%(1例)。对于随访组患者,有TWB PET/CT分期无PD亚组(n=85)、有TWB PET/CT分期有PD亚组(n=4)、无TWB PET/CT分期无PD亚组(n=43)、无TWB PET/CT分期有PD亚组(n=15)P1分别为1.2%、75.0%、0%、26.7%,P2分别为1.2%、0%、0%、13.3%。对于随访组患者,无论是否行初诊分期的TWB PET/CT检查,无PD组和有PD组的P1为0.8% vs. 36.8%(P <0.000 1),P2 为0.8% vs. 10.5%,(P<0.000 1)。
      结论  ENKTL患者初诊分期不常规推荐行头顶到脚底的TWB PET/CT显像;临床没有肿瘤进展依据或有进展依据但TWB PET/CT初诊分期时病变局限在LWB范围内的随访患者,推荐随访时常规行头顶到大腿中份的LWB PET/CT;ENKTL患者初诊分期时未行TWB PET/CT了解下肢情况,如在随访检查前出现了LWB范围内肿瘤进展的依据,随访评估时推荐行TWB PET/CT评估全身肿瘤累及情况。

     

    Abstract:
      Objective  To assess the staging, restaging, and treatment strategy determination of extranodal NK/T cell lymphoma (ENKT) by PET/CT real body (true whole-body, TWB) imaging, which is superior to PET/CT limitation of the whole body (limited whole-body, LWB, from skull vertex to upper thighs) by adding ‘distal lower extremity’ images.
      Methods  TWB 18F-FDG PET/CT studies performed for staging and follow-up of ENKTL patients between January 2012 and September 2017 were retrospectively reviewed. Patients in staging group received TWB PET/CT evaluation for staging at the first diagnosis. In follow-up group, patients received follow-up evalution with TWB PET/CT and progressive disease (PD) in the LWB range with or without clinical diagnosis or suspicion before follow-up examination, and then divided into four subgroups: staging (+) PD (-), staging (+) PD (+), staging (-) PD (-), staging (-) PD (+). Then the percentage of unexpected ENKTL lesions found at the distal extremity (outside the LWB range) (P1), and the percentage of changes in the staging, restaging/outcome evaluation (P2) in each group were recorded.
      Results   Among the 225 patients in the staging group, 200 (88.9%) had tumors confined to LWB, while P1 was 11.1% (25 cases) and P2 was 0.4% (1 case). In the follow-up group, the P1 in staging (+) PD (-)(n=85), staging (+) PD (+)(n=4), staging (-) PD (-)(n=43), staging (-) PD (+) goups (n=15) were 1.2%, 75.0%, 0%, 26.7%, and P2 were 1.2%, 0%, 0%, 13.3%, respectively. In the follow-up group, regardless of whether the TWB PET/CT examination was performed at the initial diagnosis stage, P1 in PD (-) group and PD (+) group was 0.8 vs. 36.8% (P<0.000 1), and P2 was 0.8% vs. 10.5% (P<0.000 1).
      Conclusion  It is not recommended that the TWB PET/CT imaging from the top of the head to the bottom of the foot use for the first diagnosis of ENKTL patients. And for follow-up patients with no clinical evidence of tumor progression or with evidence of tumor progression but whose lesions were limited to LWB at the initial diagnosis of TWB PET/CT staging, LWB PET/CT from the top of the head to the middle of the thigh is recommended for routine follow-up. For ENKTL patients, TWB PET/CT was not performed at the initial stage of diagnosis to detect the condition of lower limbs. If the evidence of tumor progression in the LWB range appeared before the follow-up examination, TWB PET/CT was recommended for the follow-up evaluation to evaluate the systemic tumor involvement.

     

/

返回文章
返回